IR@PKUHSC  > 北京大学第三临床医学院
学科主题临床医学
Potential roles of glucagon-like peptide-1-based therapies in treating non-alcoholic fatty liver disease
Liu, Ye; Wei, Rui; Hong, Tian-Pei
关键词Non-alcoholic Fatty Liver Disease Glucagon-like Peptide-1 Dipeptidyl Peptidase-4 Insulin Resistance Oxidative Stress Lipid Metabolism
刊名WORLD JOURNAL OF GASTROENTEROLOGY
2014-07-21
DOI10.3748/wjg.v20.i27.9090
20期:27页:9090-9097
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Gastroenterology & Hepatology
研究领域[WOS]Gastroenterology & Hepatology
关键词[WOS]TYPE-2 DIABETES-MELLITUS ; INCRETIN-BASED THERAPIES ; DIPEPTIDYL-PEPTIDASE-IV ; HEPATIC STEATOSIS ; GLUCOSE-METABOLISM ; INSULIN-RESISTANCE ; MICE ; RECEPTOR ; STEATOHEPATITIS ; DIET
英文摘要

Glucagon-like peptide-1 (GLP-1)-based therapies have demonstrated efficacy and safety in treating type 2 diabetes, which shares a similar pathophysiological mechanism with non-alcoholic fatty liver disease (NAFLD). Recent studies showed that glucose-induced GLP-1 secretion was decreased in patients with NAFLD and that the level of dipeptidyl peptidase-4, which inactivates intact GLP-1, was upregulated. Moreover, the expression of the GLP-1 receptor was downregulated in livers from patients with NAFLD, indicating an association of defective GLP-1 signalling with NAFLD. Notably, GLP-1-based therapies are reported to be effective in improving hepatic endpoints in patients with NAFLD, such as reducing hepatic fat content, hepatic steatosis and plasma transaminase levels, and preventing fibrosis. GLP-1-based therapies are beneficial for body weight control and glycaemic normalisation, which are important for the management of NAFLD. Moreover, clinical and preclinical studies showed that GLP-1-based agents might directly exert their actions on the liver through activation of functional GLP-1 receptors in hepatocytes. The possible mechanisms involve regulating gene expression that is associated with insulin resistance and lipid metabolism, and suppressing oxidative stress in the liver cells, thus preventing the development and progression of NAFLD. Based on these promising data, large-scale randomised controlled trials are warranted to assess the efficacy and safety of GLP-1-based therapies in treating NAFLD. (C) 2014 Baishideng Publishing Group Inc. All rights reserved.

语种英语
WOS记录号WOS:000339389600032
项目编号2012CB517502 ; 20120001120069
资助机构Chinese National 973 Program ; Research Fund for the Doctoral Program of Higher Education of China
引用统计
被引频次:14[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/54771
专题北京大学第三临床医学院
北京大学第三临床医学院_内分泌科
作者单位Peking Univ, Hosp 3, Dept Endocrinol & Metab, Beijing 100191, Peoples R China
推荐引用方式
GB/T 7714
Liu, Ye,Wei, Rui,Hong, Tian-Pei. Potential roles of glucagon-like peptide-1-based therapies in treating non-alcoholic fatty liver disease[J]. WORLD JOURNAL OF GASTROENTEROLOGY,2014,20(27):9090-9097.
APA Liu, Ye,Wei, Rui,&Hong, Tian-Pei.(2014).Potential roles of glucagon-like peptide-1-based therapies in treating non-alcoholic fatty liver disease.WORLD JOURNAL OF GASTROENTEROLOGY,20(27),9090-9097.
MLA Liu, Ye,et al."Potential roles of glucagon-like peptide-1-based therapies in treating non-alcoholic fatty liver disease".WORLD JOURNAL OF GASTROENTEROLOGY 20.27(2014):9090-9097.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Liu, Ye]的文章
[Wei, Rui]的文章
[Hong, Tian-Pei]的文章
百度学术
百度学术中相似的文章
[Liu, Ye]的文章
[Wei, Rui]的文章
[Hong, Tian-Pei]的文章
必应学术
必应学术中相似的文章
[Liu, Ye]的文章
[Wei, Rui]的文章
[Hong, Tian-Pei]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。